Market News & Trends
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial
Sienna Biopharmaceuticals, Inc. recently announced the first patient has been dosed in the Company’s Phase 2b clinical trial of topical product candidate SNA-120 (pegcantratinib) in…
Aclaris Therapeutics Announces the Allowance of a US Patent Application & Issuance Covering Hair Loss Disorders
Aclaris Therapeutics, Inc. recently announced that Columbia University has received a Notice of Allowance from the USPTO for a patent application covering methods of treating…
Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study
Molecular Templates, Inc. recently announced the dosing of the first patient in a Phase 1 expansion study of MT-3724, a first-generation ETB that targets the…
Cognition Therapeutics Announces Issuance of Patent for a First-in-Class Alzheimer’s Disease Clinical Candidate
Cognition Therapeutics, Inc. recently announced the USPTO has issued a composition of matter patent for a family of novel compounds including CT1812, Cognition’s first-in-class, orally…
Genisphere Pursues Neurotherapeutics Under Collaboration Agreement With Inserm
Genisphere LLC has signed a collaborative research agreement with The Institut national de la santé et de la recherche médicale (Inserm, The French National Institute…
Cognition Therapeutics Receives Fast Track Designation for First-in-Class Alzheimer’s Candidate
Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, recently…
Plasticell & GSK Sign Collaboration Agreement
Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem…
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates
AntriaBio, Inc. recently announced it is advancing the first development candidates from its oral plasma kallikrein inhibitor (PKI) portfolio. The two preclinical programs are AB402…
Ziopharm Oncology Announces First Patient Dosed in New Phase 1 Study
Ziopharm Oncology, Inc. recently announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment…
Ovid Therapeutics Announces Positive Preclinical Data
Ovid Therapeutics Inc. recently announced new positive preclinical data on OV101 that shows normalization of behavioral abnormalities that resemble those seen in people with Fragile…
Vetter to Expand its Secondary Packaging Service Capacity to Meet Rising Demands
Vetter, a global leader in prefilled drug delivery systems and an expert in complex packaging projects, recently announced a major expansion of its secondary packaging capacities…
Arcturus Therapeutics Announces Strategic Collaboration With J&J Innovation to Discover & Develop RNA Medicines
Arcturus Therapeutics, Inc., a leading RNA medicines company, recently announced today it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals,…
White Paper: Establishing cGMP Manufacturing Capability for Phase 1 Sterile, Dispersed, Injectable Dosage Forms
As a product transitions from pre-clinical development to a clinical development phase, the manufacturing process takes on a much greater role in the overall success…
Mustang Bio Announces $12.8-Million Grant to Fund Clinical Trial of CAR T Therapy
Mustang Bio, Inc., a Fortress Biotech, Inc. company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR…
Piramal Pharma Solutions Announces Large-Scale Expansion of API Manufacturing Facilities
Piramal Pharma Solutions Announces Large-Scale Expansion of API Manufacturing Facilities Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO), recently announced investments…
NanOlogy Announces First Patient Enrolled in Phase 2 Clinical Trial of NanoPac
NanOlogy LLC , a clinical-stage pharmaceutical development company, recently announced enrollment of the first patient in a Phase 2 clinical trial of intraperitoneally (IP) administered…
Cellectar Biosciences & Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
Cellectar Biosciences, Inc., an oncology-focused, clinical-stage biotechnology company, together with leading French pharmaceutical company Pierre Fabre, recently announced the extension of their ongoing collaboration to…
Study Demonstrates Benefit of West's ID Adapter for Improving Intradermal Administration of Polio Vaccine
West Pharmaceutical Services, Inc. , a global leader in innovative solutions for injectable drug administration, recently shared the results of a study highlighting the benefits…
pSivida & Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug
pSivida Corp., a leader in the development of sustained release drug products and technologies, and Nicox S.A., the international ophthalmic company, recently announced their entry…
AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis & Toxicology Risk Assessment
AMRI, a global contract research, development and manufacturing organization that partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life,…
